Products of other enterprises
Description
NEUPOGEN 300 Mg is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Other Information
- Minimum Order Quantity: 1
- Port of Dispatch: Mumbai
- Production Capacity: 10000
- Delivery Time: 10-12 days
Contact the seller
Neupogen